2000年在日本鉴定出的对新型抗菌药物佐利氟达星耐药的临床淋病奈瑟菌菌株H035的完整参考基因组序列
Complete Reference Genome Sequence of the Clinical Neisseria gonorrhoeae Strain H035, with Resistance to the Novel Antimicrobial Zoliflodacin, Identified in Japan in 2000.
作者信息
Golparian Daniel, Jacobsson Susanne, Ohnishi Makoto, Unemo Magnus
机构信息
World Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
出版信息
Microbiol Resour Announc. 2023 Mar 16;12(3):e0113022. doi: 10.1128/mra.01130-22. Epub 2023 Feb 28.
Abstract
Zoliflodacin is a promising novel antimicrobial in clinical development for treatment of gonorrhea; currently, it is in a global phase 3 randomized controlled clinical trial. High activity against global Neisseria gonorrhoeae strains has been shown. We present the complete reference genome of the zoliflodacin-resistant strain H035, which was identified in Japan in 2000.
摘要
佐利氟达辛是一种在淋病治疗临床开发中颇具前景的新型抗菌药物；目前，它正处于全球3期随机对照临床试验阶段。已显示其对全球淋病奈瑟菌菌株具有高活性。我们展示了2000年在日本鉴定出的耐佐利氟达辛菌株H035的完整参考基因组。
相似文献
1
Complete Reference Genome Sequence of the Clinical Neisseria gonorrhoeae Strain H035, with Resistance to the Novel Antimicrobial Zoliflodacin, Identified in Japan in 2000.
Microbiol Resour Announc. 2023 Mar 16;12(3):e0113022. doi: 10.1128/mra.01130-22. Epub 2023 Feb 28.
2
Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against in a gonococcal hollow-fiber infection model.
Front Pharmacol. 2023 Dec 7;14:1291885. doi: 10.3389/fphar.2023.1291885. eCollection 2023.
3
GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.
J Antimicrob Chemother. 2022 Dec 23;78(1):150-154. doi: 10.1093/jac/dkac366.
4
Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.
J Antimicrob Chemother. 2021 Oct 11;76(11):2847-2849. doi: 10.1093/jac/dkab262.
5
In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.
J Antimicrob Chemother. 2019 Dec 1;74(12):3521-3529. doi: 10.1093/jac/dkz376.
6
Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against in a Dynamic Hollow Fiber Infection Model.
Front Pharmacol. 2021 May 21;12:682135. doi: 10.3389/fphar.2021.682135. eCollection 2021.
7
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
J Antimicrob Chemother. 2021 Apr 13;76(5):1221-1228. doi: 10.1093/jac/dkab024.
8
Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of , Including Multi-Drug-Resistant Isolates.
ACS Infect Dis. 2020 Jun 12;6(6):1332-1345. doi: 10.1021/acsinfecdis.0c00021. Epub 2020 May 12.
9
Pharmacodynamic Evaluation of Zoliflodacin Treatment of Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model.
Front Pharmacol. 2022 Apr 14;13:874176. doi: 10.3389/fphar.2022.874176. eCollection 2022.
10
High susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical isolates from Thailand (2018) and South Africa (2015-2017).
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01479-19. Epub 2019 Sep 23.
引用本文的文献
1
Management and prevention of Neisseria meningitidis and Neisseria gonorrhoeae infections in the context of evolving antimicrobial resistance trends.
Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):233-250. doi: 10.1007/s10096-024-04968-8. Epub 2024 Nov 27.
2
The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy.
Pharmaceutics. 2023 Oct 29;15(11):2554. doi: 10.3390/pharmaceutics15112554.
本文引用的文献
1
GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.
J Antimicrob Chemother. 2022 Dec 23;78(1):150-154. doi: 10.1093/jac/dkac366.
2
WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study.
Lancet Microbe. 2021 Nov;2(11):e627-e636. doi: 10.1016/S2666-5247(21)00171-3. Epub 2021 Sep 2.
3
Pharmacodynamic Evaluation of Zoliflodacin Treatment of Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model.
Front Pharmacol. 2022 Apr 14;13:874176. doi: 10.3389/fphar.2022.874176. eCollection 2022.
4
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
J Antimicrob Chemother. 2021 Apr 13;76(5):1221-1228. doi: 10.1093/jac/dkab024.
5
Gonorrhoea.
Nat Rev Dis Primers. 2019 Nov 21;5(1):79. doi: 10.1038/s41572-019-0128-6.
6
Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads.
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595. doi: 10.1371/journal.pcbi.1005595. eCollection 2017 Jun.
7
NCBI prokaryotic genome annotation pipeline.
Nucleic Acids Res. 2016 Aug 19;44(14):6614-24. doi: 10.1093/nar/gkw569. Epub 2016 Jun 24.
Zotero 插件